80 likes | 227 Views
PEDIATRIC VACCINE STOCKPILES. A Status Report on the Pediatric Vaccine Stockpiles November 2005. Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Program Support Branch (PSB) Immunization Services Division (ISD) National Immunization Program (NIP). History.
E N D
PEDIATRIC VACCINE STOCKPILES A Status Report on the Pediatric Vaccine Stockpiles November 2005 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Program Support Branch (PSB) Immunization Services Division (ISD) National Immunization Program (NIP)
History • 1983 Began stockpiling pediatric vaccines • 1993 VFC legislation enacted; established requirement for 6-month stockpile of all routinely recommended childhood vaccines • 1993 Began purchasing vaccines for stockpile • 2002 Revenue recognition issues arise • 2005 All vaccine manufacturers agree to sell vaccines to CDC for stockpile
Pediatric Vaccine Stockpiles • What happened? • May 2005 - CDC met with SEC • June-July 2005 - SEC met with the corporate HQ’s of all four vaccine manufacturers • August 2005 - All of the vaccine manufacturers agreed to participate in the CDC Pediatric Vaccine Stockpile Program • Regardless of the revenue recognition issues • Based on their capacity to sell CDC vaccines for the stockpile
Pediatric Vaccine Stockpiles • Fiscal Year (FY) 2005 activity • All four manufacturers agreed in FY 2005 to sell vaccine to CDC for the Pediatric Vaccine Stockpiles • $158.8M obligated to purchase 5,500 doses • CDC established new target quantities for stockpiled vaccine • CDC established revised plans for future vaccine purchases for the stockpile
Purchased/Undelivered Doses • FY 2003 • 2.4 million doses IPV (sanofi) • 2 million doses HepB (GSK) • 1 million doses HepA (GSK) • 0.8 million doses PCV7 (Wyeth) • FY 2005 • 0.5 million doses Hib (sanofi) • 1.5 million doses DTaP (sanofi & GSK) • 2 million doses PCV7 (Wyeth) • 0.5 million doses DTaP/HepB/IPV
Pediatric Vaccine Stockpiles • Stockpile management • Target quantities workgroup • NVAC & ACIP participation • Contract review and revision • Purchase vs. delivery price • Third-party distributor
Next Steps • Review and revise contracts with two (2) manufacturers who have existing stockpile contracts • Establish new stockpile contracts with two(2) vaccine manufacturers • Incorporate stockpile management into VMBIP